Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person13
IMMUNIC, INC.
Company
Immunome Inc.
Company
ImmunityBio, Inc.
Company
Immunovant, Inc.
Company
Imunon, Inc.
Company
Altimmune, Inc.
Company
AIM ImmunoTech Inc.
Company
Evommune, Inc.
Company
HARMONIC INC.
Company
Lyell Immunopharma, Inc.
Company
IMPINJ INC
Company
UNIFI INC
Company
DUCOMMUN INC /DE/
Company
Primary record17
GeoVax Labs, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Termination of President and Chief Executive Officer On Nove
IMMUNIC, INC. filed 8-K
Item 7.01. Regulation FD Disclosure On November 5, 2026, Immunic, Inc. (the “ Company ” or “ Immunic ”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “ PMS R&D Day ”). The PM
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On November 5, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On November 4, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to
ONCOLYTICS BIOTECH INC filed 8-K
Item 8.01. Other Events. On November 4, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing translational data from its study in squamous cell anal cancer patients, specifically pelareorep's a
Cullinan Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 4, 2026, Cullinan Therapeutics, Inc. (the "Company") issued a press release announcing that the Company will present updated data from the CLN-049 Phase 1 dose escalation c
IMMUNIC, INC. filed SCHEDULE 13G/A
0001716774-26-000028.txt : 20261102 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001085146-25-004384 0001716774 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 09/30/2026 0001280776 IMMUNIC, INC. 4525EP200 1200
Coherus Oncology, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 28, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release announcing the interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, i
Climb Bio, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 24, 2026, Climb Bio, Inc. (the “Company”) issued a press release announcing initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary membran
Climb Bio, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 23, 2026, Climb Bio, Inc. (the “Company”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), issued a press release announcing results for additional Phase 1 data in healt
IONIS PHARMACEUTICALS INC filed 8-K
Item 7.01 Regulation FD Disclosure. On October 20, 2026, Ionis Pharmaceuticals, Inc. (“ Ionis ”) issued a press release reporting that its partner, GSK, announced that the U.S. Food and Drug Administration (“ FDA ”) has
Arcus Biosciences, Inc. filed 8-K
Item 8.01 Other Events. On October 20, 2026, Arcus Biosciences, Inc. presented new data from the ARC-20 platform study evaluating casdatifan, alone or in combination, as a first-, second- and late-line treatment for clea
Edesa Biotech, Inc. filed 8-K
Item 8.01. Other Events. On October 15, 2026, Edesa Biotech, Inc. (the Company ) reported that the U.S. Food and Drug Administration ( FDA ) has cleared the Company's Investigational New Drug ( IND ) application for its
Quince Therapeutics, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Officers As previously announced, effective as
Q32 Bio Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 30, 2026, Q32 Bio Inc. (the Company ) issued a press release titled Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Jade Biosciences, Inc. filed 8-K
Item 8.01. Other Events. On September 30, 2026, Jade Biosciences, Inc. ( Jade ) announced preclinical data characterizing JADE301, its anti-interferon beta ( IFN- ) monoclonal antibody in development for dermatomyositis
Cartesian Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 29, 2026, Cartesian Therapeutics, Inc. (the Company ) issued a press release announcing additional retreatment data from the Company s Phase 2 trial of Descartes-08 in pat